BioCatalystWatch
VALNWorkspace / VALN / OverviewCompany library
Valneva SE logo

Valneva SE

Valneva SE (VALN)

Website

Featured programme · VLA2112

Price
Market cap
Next catalyst—
Cash

Chart & Events

Candle interval

Core Clinical

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Other pipelines

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

Chikungunya virus (CHIKV)

PreINDP1P2P3FilingApproved
VLA2112

EBV viral glycoproteins

PreINDP1P2P3FilingApproved

Partner / License out

Vaccine

OspA

PreINDP1P2P3FilingApproved

Vaccine

Approved

PreINDP1P2P3FilingApproved

Approved / commercial

Chikungunya virus (CHIKV)

Approved

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Vaccine

Cholera toxin B (CTB)

Approved

PreINDP1P2P3FilingApproved

Vaccine

Cholera toxin B (CTB)

Approved

PreINDP1P2P3FilingApproved

Japanese encephalitis virus (JEV)

Approved

PreINDP1P2P3FilingApproved

History / paused

SARS-CoV-2 S protein

Approved

PreINDP1P2P3FilingApproved

C. difficile toxin A × C. difficile toxin B

PreINDP1P2P3FilingApproved

Financial position

Cash and cash equivalents

Source and basis

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

VALN SEC archive